Therapeutic bacteriophage compositions
Inventors
Shaw, Karen Joy • MORALES, Sandra P. • MEARNS, Gillian • RANKIN, Deborah A. • SMREKAR, Frenk
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12503687-B2
Publication Date
2025-12-23
Expiration Date
Abstract
The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, or Sa83, or mutants thereof. Also encompassed are the use of said bacteriophage compositions for medical or non-medical applications, as well as kits, bandages, and wound dressings comprising said bacteriophage compositions.
Core Innovation
The invention features bacteriophage compositions for treating bacterial infections in a human subject, directed particularly to Staphylococcus aureus pulmonary infections. The disclosure also provides a kit containing the bacteriophage composition together with instructions for therapeutic use. Documented uses further comprise surface application to kill bacteria as well as combination treatments with antibiotics.
The therapeutic three-phage panel reduces antagonism and resistance development compared with a four-phage panel that includes J-Sa37. In an experimental Staphylococcus aureus pneumonia model, phage panel administration reduces lung bacterial load with results comparable to vancomycin treatment at higher tested doses. Recovered bacterial isolates from the evaluated pneumonia model consistently maintain phage sensitivity following treatment.
Claims Coverage
The claims identify two independent claims directed to two inventive features, covering a therapeutic bacteriophage composition and a kit for treating pulmonary bacterial infection.
Therapeutic bacteriophage composition
A composition for treating bacterial infection in a human subject, comprising one or more bacteriophages selected by whole-genome sequence identity to [procedural detail omitted for safety], with quantitative dosage details omitted.
Kit for treating pulmonary bacterial infection
A kit comprising a bacteriophage composition with one or more bacteriophages selected by whole-genome sequence identity to [procedural detail omitted for safety], for use in treating pulmonary bacterial infection, together with instructions for use.
The independent claims cover a therapeutic bacteriophage composition and a corresponding kit with instructions for use, with dependent claims further addressing specific infection types, antibiotic combinations, and composition characteristics.
Stated Advantages
The three-phage panel is reported to reduce antagonism and resistance development compared with a four-phage panel that includes J-Sa37.
In a murine pneumonia model, a four-phage panel is reported to reduce lung bacterial counts, with results for the two higher tested doses described as comparable to vancomycin.
Recovered isolates in the murine pneumonia model are reported to remain phage-sensitive.
Documented Applications
Treatment of bacterial infections in a human subject, including Staphylococcus aureus infections and pulmonary bacterial infections.
A kit containing the bacteriophage composition and instructions for use in treating pulmonary bacterial infection.
Combination use with antibiotics.
Application of the bacteriophage composition to surfaces to kill bacteria.
Pulmonary delivery and incorporation into phage-containing wound dressings.
Evaluation of therapeutic efficacy in a Staphylococcus aureus pneumonia model.
Interested in licensing this patent?